People who reported side effects to the Pfizer/BioNTech and Moderna Covid-19 vaccines such as fever, chills or muscle pain tended to have a greater antibody response following vaccination. (Those with no symptoms still elicited robust immune response) https://t.co/1nNG9r18yT
People who reported experiencing side effects to the Pfizer/BioNTech and Moderna Covid-19 vaccines such as fever, chills or muscle pain tended to have a greater antibody response following vaccination, according to new research https://t.co/WkoNNQaLXV
Equity investors, including Sequoia Capital, Binance, Qatar Investment Authority and others, received the requisite paperwork for the Twitter financing commitment from Elon Musk's lawyers, a source said https://t.co/BMvCK4NPzDpic.twitter.com/mpP2GHOCJM
The clock is ticking for Elon Musk to buy Twitter — and he’s running out of time
Grace Kay
Tue, October 25, 2022 at 4:45 PM
The pressure is on for Elon Musk and his army of lawyers.
The billionaire has only four days to close his deal with Twitter or face a trial — which experts say he is likely to lose.
Earlier this month, the Delaware judge overseeing the court case gave the two parties until 5 p.m. ET on October 28 to agree to a new deal or the case will resume in a five-day trial in November.
Judge Kathaleen St. J. McCormick is unlikely to offer an extension and would favor a quick start for the trial if Musk misses the deadline, University of Michigan business law professor Erik Gordon told Insider. .
If the two parties don’t reach an agreement before Friday, they could technically continue to negotiate even as litigation resumes and a trial date is scheduled.
But a continued court battle is unlikely to do Musk any favors.
“He knows that he has no way out of it and would like to avoid public humiliation,” Alon-Beck told Insider.
If the trial were to proceed, Musk would face a lengthy deposition and could see even more of his private texts released to the public, Gerard Filitti, senior counsel at The Lawfare Project, an international non-profit legal think tank and litigation fund based in New York City, previously told Insider. .
The researchers emphasize that unless clinical trials are conducted and GABA is approved for treating COVID-19 by relevant governing bodies, it should not be consumed for the treatment of COVID-19 since it could pose health risks, such as dampening beneficial immune or physiological responses.
γ-Aminobutyric acid, or GABA, is the chief inhibitory neurotransmitter in the developmentally mature mammalian central nervous system. Its principal role is reducing neuronal excitability throughout the nervous system. GABA is sold as a dietary supplement in many countries. Wikipedia
This article is a preprint. Preprints have not been peer reviewed.
.
Study Shows Inexpensive, Readily Available Chemical May Limit Impact of COVID-19
Preclinical studies in mice that model human COVID-19 suggest that an inexpensive, readily available amino acid might limit the effects of the disease.
Newswise — Preclinical studies in mice that model human COVID-19 suggest that an inexpensive, readily available amino acid might limit the effects of the disease and provide a new off-the-shelf therapeutic option for infections with SARS-CoV-2 variants and perhaps future novel coronaviruses.
A team led by researchers at the David Geffen School of Medicine at UCLA report that an amino acid called GABA, which is available over-the-counter in many countries, reduced disease severity, viral load in the lungs, and death rates in SARS-CoV-2-infected mice. This follows up on their previous finding that GABA consumption also protected mice from another lethal mouse coronavirus called MHV-1. In both cases, GABA treatment was effective when given just after infection or several days later near the peak of virus production. The protective effects of GABA against two different types of coronaviruses suggest that GABA may provide a generalizable therapy to help treat diseases induced by new SARS-CoV-2 variants and novel beta-coronaviruses.
…Their previous studies showed that GABA administration protected mice from developing severe disease after infection with a mouse coronavirus called MHV-1. To more stringently test the potential of GABA as a therapy for COVID-19, they studied transgenic mice that when infected with SARS-CoV-2 develop severe pneumonia with a high mortality rate. “If our observations of the protective effects of GABA therapy in SARS-CoV-2-infected mice are confirmed in clinical trials, GABA could provide an off-the-shelf treatment to help ameliorate infections with SARS-CoV-2 variants. GABA is inexpensive and stable at room temperature, which could make it widely and easily accessible, and especially beneficial in developing countries.” .
Working with colleagues at the University of Southern California, the UCLA research team in this study administered GABA to the mice just after infection with SARS-CoV-2, or two days later when the virus levels are near their peak in the mouse lungs. While the vast majority of untreated mice did not survive this infection, those given GABA just after infection, or two days later, had less illness severity and a lower mortality rate over the course of the study. Treated mice also displayed reduced levels of virus in their lungs and changes in circulating immune signaling molecules, known as cytokines and chemokines, toward patterns that were associated with better outcomes in COVID-19 patients. Thus, GABA receptor activation had multiple beneficial effects in this mouse model that are also desirable for the treatment of COVID-19. .
The researchers emphasize that unless clinical trials are conducted and GABA is approved for treating COVID-19 by relevant governing bodies, it should not be consumed for the treatment of COVID-19 since it could pose health risks, such as dampening beneficial immune or physiological responses.
